Breast cancer test from NanoString gains FDA clearance

09/10/2013 | GenomeWeb Daily News (free registration)

The FDA has cleared NanoString Technologies to market its Prosigna Breast Cancer Prognostic Gene Signature Assay, which runs on the company's nCounter Dx Analysis System. The assay is used to assess distant recurrence-free survival in postmenopausal women with certain types of breast cancer 10 years after undergoing surgery, the company said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY